Home » Stocks » ACER

Acer Therapeutics Inc. (ACER)

Stock Price: $3.10 USD 0.05 (1.64%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $3.13 +0.03 (0.97%) Jun 11, 6:15 PM
Market Cap 44.36M
Revenue (ttm) 4.00M
Net Income (ttm) -19.45M
Shares Out 14.14M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $3.10
Previous Close $3.05
Change ($) 0.05
Change (%) 1.64%
Day's Open 3.04
Day's Range 3.01 - 3.14
Day's Volume 89,526
52-Week Range 2.15 - 5.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 days ago - Zacks Investment Research

NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercializat...

2 weeks ago - GlobeNewsWire

NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rar...

3 weeks ago - GlobeNewsWire

NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r...

2 months ago - GlobeNewsWire

NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

2 months ago - GlobeNewsWire

Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) have entered into a Collaboration and License Agreement for worldwide development and commercialization of ACER-0...

Other stocks mentioned: RLFTF
2 months ago - Benzinga

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights

2 months ago - GlobeNewsWire

Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics. The post ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing High...

2 months ago - InvestorPlace

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Other stocks mentioned: MGM, XPEV
2 months ago - Benzinga

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r...

3 months ago - GlobeNewsWire

Targeting a pre-NDA meeting with FDA in Q2 2021 Targeting a pre-NDA meeting with FDA in Q2 2021

4 months ago - GlobeNewsWire

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief

4 months ago - GlobeNewsWire

Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021 Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021

5 months ago - GlobeNewsWire

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

7 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $ACER #ACER--ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc.

8 months ago - Business Wire

NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

8 months ago - GlobeNewsWire

NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ...

9 months ago - GlobeNewsWire

Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders

10 months ago - GlobeNewsWire

SAN DIEGO & NEWTON, Mass.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc.

10 months ago - Business Wire

SAN DIEGO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NY...

11 months ago - Business Wire

Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current trea...

11 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $ACER #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (“Acer” or the “Company”)...

11 months ago - Business Wire

Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital Expanded pipeline with a...

1 year ago - GlobeNewsWire

NEWTON, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...

1 year ago - GlobeNewsWire

Per IDC, PC shipments decline 9.8% in Q1 despite strong demand, as the global lockdown hurt supply chains and productions all over.

Other stocks mentioned: HPQ, LNVGY, AAPL, DELL
1 year ago - Zacks Investment Research

Acer Therapeutics: EDSIVO Appeal Denied But FDA Door Remains Open

1 year ago - Seeking Alpha

Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™ Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™

1 year ago - GlobeNewsWire

Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data Anticipate submitting New Drug Application i...

1 year ago - GlobeNewsWire

Acer Therapeutics: Upcoming Catalysts

1 year ago - Seeking Alpha

Part A Successfully Completed and Optimal Formulation of ACER-001 Identified

1 year ago - GlobeNewsWire

Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021 Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

1 year ago - GlobeNewsWire

There are several good reasons that two consecutive quarters of improved personal computer purchases could become three, and then four, or more.

Other stocks mentioned: DELL, AAPL, HPQ, LNVGY
1 year ago - The Motley Fool

Acer's share price plummeted following a CRL issued by the FDA in late June for Acer's lead drug candidate EDSIVO for the treatment of vEDS patients with COL3A1 + mutation.

1 year ago - Seeking Alpha

NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ...

1 year ago - GlobeNewsWire

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Other stocks mentioned: BHVN, CELG, ITCI, KPTI, MRK
1 year ago - Benzinga

Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

1 year ago - Zacks Investment Research

Acer Therapeutics news for Tuesday concerning a rejection letter from the U.S. Food and Drug Administration is pummeling ACER stock.

1 year ago - InvestorPlace

Acer Therapeutics Inc (NASDAQ: ACER) shares were trading down more than 75% Tuesday after it received a letter from the Food and Drug Administration regarding its drug application for Edsivo in the trea...

1 year ago - Benzinga

Acer Therapeutics Inc. said Tuesday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its new drug application (NDA) for Edsivo, a treatment of vascular E...

1 year ago - Market Watch

Acer Therapeutics has 3 clinical stage drug candidates targeting serious orphan and ultra-orphan diseases with significant unmet medical needs.

2 years ago - Seeking Alpha

Laura Chico maintained an Outperform rating on Acer Therapeutics with an unchanged $48 price target.

2 years ago - Benzinga

Acer's share price has recently dropped significantly along with other biotech companies.

2 years ago - Seeking Alpha

About ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatme... [Read more...]

Industry
Biotechnology
Founded
2013
CEO
Christopher Schelling
Employees
21
Stock Exchange
NASDAQ
Ticker Symbol
ACER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACER stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 222.58% from the latest price.

Price Target
$10.00
(222.58% upside)
Analyst Consensus: Buy